Publication:
Iron homeostasis alterations and risk for akathisia in patients treated with antipsychotics: A systematic review and meta-analysis of cross-sectional studies.

cris.virtualsource.author-orcid94cc1dd7-9dd1-48ee-9b3e-dce1c3c31412
datacite.rightsopen.access
dc.contributor.authorSchoretsanitis, Georgios
dc.contributor.authorNikolakopoulou, Adriani
dc.contributor.authorGuinart, Daniel
dc.contributor.authorCorrell, Christoph U
dc.contributor.authorKane, John M
dc.date.accessioned2024-09-02T15:56:34Z
dc.date.available2024-09-02T15:56:34Z
dc.date.issued2020-06
dc.description.abstractIron homeostasis may be implicated in the pathophysiology of antipsychotic-related akathisia. We performed a systematic review in six databases from database inception until 03/2020, conducting a meta-analysis of studies investigating iron metabolism in antipsychotic-treated patients with versus without akathisia. Using a fixed- and a random-effects model, standardized mean difference (SMD) was estimated for levels of iron, ferritin, transferrin and total iron-binding capacity. Meta-regression analyses included sex, age, illness duration and antipsychotic treatment and dose. Subgroup analyses included chronic vs. acute akathisia and different diagnoses. Study quality was assessed using the Newcastle-Ottawa scale. In 10 studies (n = 395), compared to non-akathisia patients (n = 213), iron levels were lower in patients with akathisia (n = 182; fixed-effect model: SMD=-0.49, 95%CI=-0.28,-0.70, p<0.001; random-effects model: SMD=-0.55, 95%CI=-0.14,-0.96, p = 0.008). For secondary outcomes, differences were significant regarding lower ferritin levels in patients with akathisia in the fixed-effect model (SMD=-0.32, 95%CI=-0.08,-0.55, p = 0.007), but not in the random-effects model (SMD=-0.29, 95%CI=0.20,-0.79, p = 0.24). None of the moderators/mediators had a significant effect on the group difference of iron levels. Subgroup analyses reported lower iron levels in both patients with chronic and acute akathisia vs. patients without. Iron levels for schizophrenia patients were lower in the fixed-effect model (SMD=-0.55, 95%CI=-0.23, -0.86, p<0.001), while a trend was observed in the random-effects model (SMD=-0.52, 95%CI=-0.07, -1.12, p = 0.08). The studies' quality was overall poor, with one exception. This meta-analysis suggests lower iron levels in akathisia patients, while ferritin differences were significant only in the fixed-effect model. Further data are required to promote the understanding of related pathways.
dc.description.numberOfPages11
dc.description.sponsorshipInstitut für Sozial- und Präventivmedizin (ISPM)
dc.identifier.doi10.7892/boris.144319
dc.identifier.pmid32444336
dc.identifier.publisherDOI10.1016/j.euroneuro.2020.04.001
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/36062
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofEuropean neuropsychopharmacology
dc.relation.issn0924-977X
dc.relation.organizationDCD5A442BECFE17DE0405C82790C4DE2
dc.subjectAkathisia Antipsychotic Iron Iron metabolism Meta-analysis Movement disorders
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.subject.ddc300 - Social sciences, sociology & anthropology::360 - Social problems & social services
dc.titleIron homeostasis alterations and risk for akathisia in patients treated with antipsychotics: A systematic review and meta-analysis of cross-sectional studies.
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage11
oaire.citation.startPage1
oaire.citation.volume35
oairecerif.author.affiliationInstitut für Sozial- und Präventivmedizin (ISPM)
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.date.embargoChanged2021-05-20 00:30:03
unibe.date.licenseChanged2020-06-10 09:37:44
unibe.description.ispublishedpub
unibe.eprints.legacyId144319
unibe.journal.abbrevTitleEur Neuropsychopharmacol
unibe.refereedtrue
unibe.subtype.articlejournal

Files

Original bundle
Now showing 1 - 2 of 2
Name:
Schoretsanitis EurNeuropsychopharmacol 2020_AAM.pdf
Size:
910.09 KB
Format:
Adobe Portable Document Format
License:
https://creativecommons.org/licenses/by-nc-nd/4.0
Content:
accepted
Name:
Schoretsanitis EurNeuropsychopharmacol 2020.pdf
Size:
1.52 MB
Format:
Adobe Portable Document Format
License:
publisher
Content:
published

Collections